Component

Hepatic and peripheral insulin sensitivity in diabetic rats

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Four weeks of phlorizin lowered hyperglycemia and normalized clamp-measured hepatic and peripheral insulin action in neonatal-streptozotocin diabetic rats without changing insulin secretion or pancreatic insulin content.

    Experimental context and source evidence
    dose
    Chronic phlorizin by osmotic minipump
    duration
    4 weeks
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Adult rats with neonatal-streptozotocin-induced diabetes
    limitations
    The study supports reversal of glucose toxicity in this rat model, not direct insulin-receptor agonism or human use.
    nutrient_topic
    Phlorizin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Phlorizin
    organism
    Adult rats with neonatal-streptozotocin-induced diabetes
    plain_language
    Four weeks of phlorizin lowered hyperglycemia and normalized clamp-measured hepatic and peripheral insulin action in neonatal-streptozotocin diabetic rats without changing insulin secretion or pancreatic insulin content.
    primary_references
    Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. (1990). https://pubmed.ncbi.nlm.nih.gov/2198430/ DOI: 10.1016/0026-0495(90)90120-2
    route
    Parenteral infusion
    tissue
    Euglycemic-hyperinsulinemic clamp and insulin secretion

    Phlorizin: mechanism of action and interactions (2026-09-20) · lines 99–108

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adult rats with neonatal-streptozotocin-induced diabetes · source_derived_draft · unverified_draft

    ## phlorizin-diabetic-rat-insulin-sensitivity Four weeks of phlorizin lowered hyperglycemia and normalized clamp-measured hepatic and peripheral insulin action in neonatal-streptozotocin diabetic rats without changing insulin secretion or pancreatic insulin content. Model/species: Adult rats with neonatal-streptozotocin-induced diabetes Tissue/system: Euglycemic-hyperinsulinemic clamp and insulin secretion Exposure: Chronic phlorizin by osmotic minipump Route: Parenteral infusion Duration: 4 weeks Limits: The study supports reversal of glucose toxicity in this rat model, not direct insulin-receptor agonism or human use. Primary reference: Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. (1990). https://pubmed.ncbi.nlm.nih.gov/2198430/ DOI: 10.1016/0026-0495(90)90120-2 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards